-
Syntrix to Collaborate with NCI to Study SX-682 – Cooperative Research and Development Agreement (CRADA) Assesses SX-682 Alone and In Various Combinations
-Syntrix today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute…
0 -
Syntrix Receives $2.3M Grant to Conduct a Phase 1/2 Clinical Trial Evaluating SX-682 Alone and with Pembrolizumab in Metastatic Melanoma
-Syntrix announced today the award of a $2.3 million grant from the National Cancer Institute (NCI) of the National Institutes…
-
Study Published in Nature Provides Path for New Immunotherapy to Prostate Cancer Using SX-682 – Results Underpin Clinical Trial of SX-682 With Anti-PD1 and Anti-CTLA4 Combination
-Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, is made “hot” by the addition of SX-682,…
-
Syntrix Wins U.S. Patent 9,480,694 – Thiopyrimidinecarboxamide for Use in Treating Pulmonary Disease
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
-
Syntrix Receives $2.965M Grant to Conduct a Phase Ib Clinical Trial Investigating Omnitram for the Treatment of Pain in Patients Resistant to Tramadol
-Syntrix announced today the award of a $2.965 million grant from the National Institute on Drug Abuse (NIDA) of the…
-
Syntrix to Present at the 2016 Needham & Company 15th Annual Healthcare Conference
-Syntrix today announced that John A. Zebala, M.D., PhD, President and Chief Executive Officer, is scheduled to present at the…
-
Syntrix Opens Investigational New Drug (IND) Application for SX-682, a Dual CXCR1 and CXCR2 Inhibitor
-Syntrix today announced that it has opened an Investigational New Drug (IND) application with the U.S. Food and Drug Administration…
-
Syntrix publication in Bioorganic & Medicinal Chemistry Letters
-Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters. Abstract: The…
-
Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial Investigating Omnitram for the treatment of Diabetic Neuropathic Pain
-Syntrix announced today the award of a $1.725 million grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to perform a clinical study investigating the
-
Syntrix wins U.S. patent 8,748,623: Pyridinecarboxamides as CXCR2 modulators
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
News
Syntrix Pharmaceuticals > News